RETROSPECTIVE ANALYSIS OF THE IMPACTS OF TREATMENT REGIMENS ON THE PROGRESSION AND PROGNOSIS OF DIABETIC RETINOPATHY AND VISUAL ACUITY IN TRAKYA UNIVERSITY SCHOOL OF MEDICINE

Yıl 2021, Cilt: 8 Sayı: 1, 17 - 21, 28.02.2021

Mustafa Ömer İzzettinoğlu Rüveyde Garip

Öz

Aims: To retrospectively analyze the impacts of treatment regimens on progression and prognosis of diabetic retinopathy and visual acuity in Trakya University Hospital. Methods: This retrospective cross-sectional study was conducted with patients who were diagnosed with diabetic retinopathy in the Ophthalmology Department of Trakya University Hospital between January 2006 and January 2020. Results: Initially, 798 eyes from 399 patients diagnosed with diabetic reti- nopathy met the inclusion criteria. Non-proliferative diabetic retinopathy was present on 202 (50.6%) patients, and 197 (49.4%) patients had proliferative diabet- ic retinopathy. Twenty-five patients (6.2%) had proliferative diabetic retinopathy progression. Patients with proliferative diabetic retinopathy progression had no difference in terms of cataract surgery, gender, and hypertension existence than the ones who did not experience proliferative diabetic retinopathy progression. There was no relation between stability, increase or decrease of visual acuity, the type of diabetes, retinal laser photocoagulation treatment, and the type of in- travitreal injection. Conclusion: Our study showed that retinal laser photocoagulation treatment and cataract surgery had no significant impact on visual acuity prognosis, unlike the initial examination visual acuity values. Additionally, it was also shown that the different types of intravitreal injections made no dissimilar results on visual acuities. In addition, in our study, it was revealed that gender, presence of hypertension, and cataract surgery may not have a significant relation with proliferative diabetic retinopathy progression. Further studies are needed to thoroughly reveal the relation between the treatment regimens, progression, and prognosis of the disease.

Anahtar Kelimeler

Diabetes mellitus, diabetic retinopathy, epidemiology, macular edema

Kaynakça

• 1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 2010;376(9735):124- 36.
• 2. Hou Y, Cai Y, Jia Z et al. Risk factors and prevalence of diabetic retinopathy: a protocol for meta-analysis. Medicine 2020;99(42):1-3.
• 3. Watkins PJ. Diabetic complications: retinopathy. Br Med J 1982;285(6339):425-7.
• 4. Heng LZ, Comyn O, Peto T et al. Diabetic retinopathy: pathogenesis, clinical grading, management and future developments. Diabet Med 2013;30(6):640-50.
• 5. Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic retinopathy. Prim Care 2015;42(3):451-64.
• 6. Zhang X, Saaddine JB, Chou CF et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010;304(6):649-56.
• 7. Fong DS, Aiello L, Gardner TW et al. Retinopathy in diabetes. Diabetes Care 2004;27(1):84-7.
• 8. Saaddine JB, Honeycutt AA, Narayan KMV et al. Projection of diabetic retinop- athy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. Arch Ophthalmol 2008;126(12):1740-7.
• 9. Matthews DR, Stratton IM, Aldington SJ et al. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 2004;122(11):1631-40.
• 10. Cui Y, Zhang M, Zhang L et al. Prevalence and risk factors for diabetic retinopathy in a cross-sectional population-based study from rural southern China: Donggu- an eye study. BMJ Open 2019;9:e023586.
• 11. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61(3):1086-97.
• 12. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vas- cular outcomes in patients with type 2 diabetes. New Engl J Med 2008;358(24): 2560-72.
• 13. Trento M, Passera P, Bajardi M et al. Lifestyle intervention by group care prevents deterioration of type II diabetes: A 4-year randomized controlled clinical trial. Diabetologia 2002;45(9):1231-9.
• 14. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl J Med 2003;348(5):383-93.
• 15. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28(2):103-17.
• 16. Lin S, Gupta B, James N et al. Visual impairment certification due to diabetic retinopathy in North and Eastern Devon. Acta Ophthalmol 2017;95(8):756-62.
• 17. Ruia S, Saxena S, Prasad S et al. Correlation of biomarkers thiobarbituric acid reactive substance, nitric oxide and central subfield and cube average thickness in diabetic retinopathy: A cross-sectional study. Int J Retina Vitreous 2016;2(8):1-7.
• 18. Gopalakrishnan S, Muralidharan A, Susheel SC et al. Improvement in distance and near visual acuities using low vision devices in diabetic retinopathy. Indian J Ophthalmol 2017;65(10):995-8.
• 19. Arthur E, Young SB, Elsner AE et al. Central macular thickness in diabetic pa- tients: a sex-based analysis. Optom Vis Sci 2019;96(4):266-75.
• 20. Panozzo G, Staurenghi G, Mura GD et al. Prevalence of diabetes and diabetic macular edema in patients undergoing senile cataract surgery in Italy: The diabe- tes and cataract study. Eur J Ophthalmol 2020;30(2):315-20.
• 21. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photo- graphic risk factors for progression of diabetic retinopathy. ETDRS report num- ber 12. Ophthalmology 1991;98(5):823-33.
• 22. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107(2):244-9.
• 23. Leske MC, Wu SY, Hennis A et al. Nine-year incidence of diabetic retinopathy in the Barbados eye studies. Arch Ophthalmol 2006;124(2):250-5.
• 24. Jeng CJ, Hsieh YT, Yang CM et al. Diabetic retinopathy in patients with diabetic nephropathy: development and progression. PLoS One 2016;11(8):e0161897.
• 25. Schorr SG, Hammes H-P, Müller UA et al. Te prevention and treatment of retinal complications in diabetes. Dtsch Arztebl Int 2016;133(48):816-23.
• 26. Baker CW, Glassman AR, Beaulieu WT et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA 2019;321(19):1880-94.
• 27. Bressler SB, Beaulieu WT, Glassman AR et al. Panretinal photocoagulation versus ranibizumab for proliferative diabetic retinopathy: Factors associated with vision and edema outcomes. Ophthalmology 2018;125(11):1776-83.